Folate (vitamin B9) is an essential micronutrient required for DNA synthesis, cell division, and 1-carbon metabolism. Serum folate reflects recent dietary intake and is the standard screening test in Swedish healthcare; low levels increase the risk of megaloblastic anemia and elevated homocysteine, particularly concerning in pregnancy where deficiency raises the risk of neural tube defects.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you are a woman planning pregnancy, currently pregnant, or have a family history of neural tube defects or pernicious anemia, a folate test is essential. Folate deficiency can develop silently — it increases homocysteine, impairs DNA replication, and causes megaloblastic anemia that is clinically indistinguishable from B12 deficiency at the morphological level.
Sweden does not mandate food fortification with folic acid, unlike the US, Canada, and UK. This means folate deficiency is more common in Swedish populations and requires proactive screening. Testing is particularly important if you have malabsorption, follow a restrictive diet, use methotrexate or certain anticonvulsants, or consume significant alcohol.
Identifies deficiency before anemia develops. Serum folate drops before hemoglobin falls, making it an early warning signal for nutritional depletion.
Guides preconception and pregnancy planning. Swedish public health guidance recommends 400 µg/day folic acid supplementation for women planning pregnancy; baseline testing determines if supplementation is adequate or excess.
Clarifies the cause of macrocytic anemia. When combined with B12 and homocysteine, folate testing distinguishes between folate deficiency, B12 deficiency, and alcohol-related macrocytosis.
Detects homocysteine elevation. Low folate raises homocysteine, a risk factor for vascular disease and thrombosis; normalizing folate lowers homocysteine and reduces this risk.
Reveals malabsorption or medication effects. Celiac disease, IBD, methotrexate, trimethoprim, and phenytoin all lower folate; testing identifies these interactions.
Prevents the pernicious anemia trap. High folate supplementation can mask the hematologic signs of B12 deficiency (normal MCV, normal hemoglobin) while neurological damage from B12 deficiency progresses silently — always check B12 before repleting folate.
The essential cofactor for 1-carbon metabolism. Folate (the active form of vitamin B9) exists in the body as tetrahydrofolate (THF), a coenzyme that accepts and transfers 1-carbon units — methyl, formyl, and methylenyl groups — to build nucleotides (the building blocks of DNA and RNA). Without folate, cells cannot synthesize new DNA, divide properly, or maintain healthy epigenetic regulation. RBC precursors (erythroblasts) are particularly sensitive to folate deficiency because they divide rapidly; when folate is depleted, they attempt division but fail to complete DNA replication, producing abnormally large, immature RBCs called megaloblasts.
Serum vs. RBC folate. Serum folate reflects dietary intake over days to weeks and drops quickly when intake is inadequate. RBC folate (measured less commonly) reflects tissue stores and longer-term status over months, but is not routine in Swedish laboratories. Serum folate is the standard first-line test in vårdcentral practice.
Why deficiency matters in pregnancy. During the first trimester, neural tube closure depends on rapid cell division and accurate DNA replication in the developing embryo. Folate deficiency impairs this process, increasing the risk of neural tube defects (spina bifida, anencephaly). This is why Swedish public health authorities recommend 400 µg/day of folic acid supplementation for women planning pregnancy and continuing through the first trimester — evidence from the UK, US, and Nordic countries shows this prevents 50–70% of neural tube defect cases.
Prevents megaloblastic anemia and cognitive decline. Folate deficiency causes megaloblastic anemia (immature, oversized RBCs that cannot carry oxygen efficiently) and impairs cognitive function and methylation capacity; in older adults, this accelerates decline in memory and executive function.
Controls homocysteine, a modifiable vascular risk factor. Folate, B12, and B6 are the primary determinants of homocysteine metabolism. Low folate raises homocysteine, which damages the endothelium, promotes atherosclerosis, and increases thrombotic risk — normalizing folate lowers homocysteine and reduces cardiovascular and stroke risk.
Supports epigenetic regulation and cancer prevention. 1-carbon metabolism drives DNA methylation, which silences oncogenic genes and maintains chromatin stability. Folate deficiency impairs methylation, increasing mutation rate and cancer risk — particularly colorectal cancer.
Identifies the pernicious anemia trap before neurological damage occurs. B12 and folate deficiencies both cause megaloblastic anemia and elevated homocysteine, but only B12 deficiency causes irreversible neurological damage (subacute combined degeneration, peripheral neuropathy, cognitive decline). If folate is repleted aggressively without first confirming B12 status, the anemia resolves and masks the underlying B12 deficiency, while neurological damage progresses silently — this is why B12 must always be tested and replete before or alongside folate.
Standard Swedish reference (vårdcentralen): > 10 nmol/L (approximately > 4.4 ng/mL) is considered normal. Below this threshold, clinical deficiency is likely.
Loovi optimal (longevity): 15–25 nmol/L. This range reflects adequate tissue stores and supports DNA synthesis, methylation, and erythropoiesis without excess.
Preconception and pregnancy target: > 20 nmol/L. Women planning pregnancy or in early pregnancy should maintain higher folate levels to ensure neural tube closure and fetal development.
Values below 10 nmol/L warrant investigation for cause (malabsorption, restrictive diet, medication effects) and supplementation. Values above 30 nmol/L are safe but do not provide additional longevity benefit. Importantly, a borderline serum folate (10–15 nmol/L) combined with elevated homocysteine indicates functional folate deficiency and warrants treatment, even if the value falls within the lab's "normal" range.
Low folate (< 10 nmol/L). Low serum folate indicates depletion of circulating folate and the beginning of tissue depletion. Symptoms may be absent initially, but over weeks to months, the body cannot maintain adequate DNA synthesis and RBC maturation — this leads to macrocytic anemia (elevated MCV, low hemoglobin) with neurological and cognitive symptoms. Low folate also raises homocysteine, accelerating vascular risk. Low folate is almost always a marker of inadequate intake, malabsorption, or medication effect, not genetic deficiency.
Optimal folate (15–25 nmol/L). This range reflects adequate stores and normal DNA synthesis, RBC maturation, and methylation capacity. Homocysteine is typically normal at this level. No intervention is needed unless intake patterns suggest risk of decline.
High folate (> 30 nmol/L). High folate is unusual from diet alone in Sweden (which lacks food fortification) but can occur with supplementation or in cases of megaloblastic anemia where folate is being repleted. High folate is safe; the body excretes excess folate in urine. However, in a patient with undiagnosed B12 deficiency, high folate can mask the hematologic signs of B12 deficiency (normal MCV, normal RBC count) while allowing neurological damage to progress — this is the pernicious anemia trap. Always confirm B12 status before or alongside folate repletion.
Factors that influence folate. Serum folate is sensitive to recent dietary intake, malabsorption (celiac, IBD, Crohn disease), medications (methotrexate, trimethoprim, phenytoin, sulfasalazine), chronic alcohol use, pregnancy, lactation, and hemolytic anemia (which increases RBC turnover and folate demand). Acute illness, inflammation, and high metabolic demand (exercise, infection, fever) can transiently lower serum folate. Testing 3 days after intense exercise or acute illness may not reflect true tissue status.
Dietary insufficiency. Folate is abundant in leafy greens, legumes, asparagus, and avocado, but is heat-labile (destroyed by cooking) and oxidation-sensitive. Restrictive diets (very low vegetable intake, low legume consumption, processed-food-heavy diets) are the most common cause of folate depletion in Sweden. Unlike the US, UK, and Canada, Sweden does not fortify staple grains with folic acid, making dietary folate intake the sole source.
Malabsorption and gastrointestinal disease. Celiac disease, Crohn disease, ulcerative colitis, and tropical sprue damage the small intestinal mucosa where folate is absorbed. Folate is absorbed primarily in the jejunum via the reduced folate carrier; even mild mucosal inflammation impairs uptake. Blind loop syndrome, bacterial overgrowth, and post-gastrectomy states also reduce folate absorption.
Medication effects. Methotrexate inhibits dihydrofolate reductase and depletes intracellular folate stores; trimethoprim (antibacterial) also inhibits this enzyme; phenytoin and other anticonvulsants impair absorption; sulfasalazine competes for absorption. Chronic alcohol use impairs absorption and damages the liver, reducing folate storage capacity.
Increased demand. Pregnancy, lactation, rapid cell proliferation (malignancy, hemolytic anemia), hyperthyroidism, and severe infection all increase folate turnover. Homozygous MTHFR polymorphisms can impair folate metabolism, though the clinical significance is debated.
Age and comorbidity. Elderly populations have lower folate intake and higher rates of malabsorption; metformin use (common in diabetes) may mildly reduce B12 and folate absorption.
Dietary optimization. Increasing intake of folate-rich whole foods — leafy greens (spinach, kale, arugula), legumes (lentils, chickpeas, black beans), asparagus, Brussels sprouts, broccoli, avocado, and fortified grains (outside Sweden, common in many European countries) — is the first-line approach. Folate is heat-labile; light steaming or raw consumption preserves more folate than prolonged cooking. For individuals with adequate intake but persistent low serum folate, malabsorption should be investigated.
Supplementation and folic acid vs. methylfolate. Folic acid (the synthetic form) is the standard supplement and is well-absorbed when taken orally with food. Swedish public health guidance recommends 400 µg/day for women planning pregnancy and during the first trimester. For individuals with diagnosed deficiency or malabsorption, 1–5 mg/day of folic acid by mouth or 5 mg/week by intramuscular injection (for severe malabsorption) is typical. Methylfolate (the active form) is also available but offers no advantage over folic acid in most individuals and is more expensive. The body converts folic acid to its active form efficiently.
Address underlying causes. If malabsorption is identified, treating the underlying condition (celiac disease requires gluten avoidance; IBD requires appropriate medical management) is essential. If methotrexate, trimethoprim, or phenytoin is the cause, discussion with the prescribing physician about dose reduction or alternative agents may be warranted. If alcohol use is contributing, reduction or cessation will improve folate stores and overall liver function.
Always confirm B12 status first. Before aggressively repleting folate, B12 must be checked. If B12 is low or borderline, it must be repleted first or simultaneously with folate. Replicating folate alone in the setting of undiagnosed B12 deficiency is dangerous — it will correct the anemia and homocysteine, masking the hematologic signs of B12 deficiency while allowing neurological damage to progress. This pernicious anemia trap is the most critical safety issue in folate repletion.
The right intervention depends on the cause of deficiency — dietary insufficiency requires food-first approach; malabsorption requires addressing the GI condition; medication-induced deficiency may require dose adjustment or alternative agents — which is why consultation with a longevity doctor is valuable to map out the full picture.
A single low folate result is medically incomplete. Folate works alongside vitamin B12 and homocysteine — B12 and folate deficiencies both cause megaloblastic anemia and elevated homocysteine, but only B12 deficiency causes irreversible neurological damage. Without checking B12 concurrently, you cannot safely replicate a low folate result. Similarly, hemoglobin and mean corpuscular volume (MCV) show whether anemia is present; ferritin and iron studies reveal whether iron deficiency is contributing to anemia; and homocysteine clarifies whether folate is low enough to impair methylation and vascular health.
This is why Loovi's membership tracks 120+ biomarkers annually, including the full B-vitamin panel (B12, folate, methylmalonic acid), hemoglobin, MCV, homocysteine, iron studies, and inflammatory markers. A longevity doctor interprets folate in context — looking for concordance or discordance between markers, identifying the root cause of depletion, ruling out pernicious anemia, and avoiding the dangerous trap of high-dose folate masking neurological B12 deficiency. You also get ongoing monitoring to ensure supplementation is working and to detect new causes of deficiency.
Yes. Folate deficiency develops in stages: serum folate drops first, then tissue folate becomes depleted, then megaloblastic changes appear in the bone marrow, and finally hemoglobin falls and anemia becomes clinically apparent. In the early stages, you may have low serum folate with normal hemoglobin and MCV. However, even at this stage, you will have elevated homocysteine, impaired DNA methylation, and reduced cognitive performance. This is why testing folate during screening — before anemia develops — is a longevity advantage.
This is functional folate deficiency. Standard laboratory interpretation calls this folate level "normal," but in the context of elevated homocysteine, it indicates that folate is inadequate for your body's 1-carbon metabolism. You should be treated as if your folate is truly low — either by dietary optimization or supplementation. This is particularly important if you also have low B12 or elevated methylmalonic acid, which would indicate concurrent B12 deficiency.
Folate is the naturally occurring form found in foods; folic acid is the synthetic form used in supplements and fortified foods. The body converts folic acid to its active form (tetrahydrofolate) via dihydrofolate reductase. Most people convert folic acid efficiently; some individuals with MTHFR polymorphisms may convert more slowly, but this rarely causes clinical problems. Folic acid is the standard, well-studied, inexpensive supplement form. If you prefer methylfolate (the active form), it is also safe but more expensive and offers no clear advantage in most people.
The US, Canada, UK, Australia, and many other countries mandate folic acid fortification of grain products (flour, bread, cereals). This reduces the population prevalence of folate deficiency dramatically and prevents many cases of neural tube defects. Sweden does not have mandatory folic acid fortification of staple grains, which means Swedish populations rely entirely on dietary intake of folate from fresh vegetables and legumes. This makes folate deficiency more common in Sweden and makes dietary counseling and supplementation for pregnant women more critical.
Yes, and this is the pernicious anemia trap. High folate supplementation (especially > 5 mg/day) can correct the megaloblastic anemia caused by B12 deficiency — hemoglobin rises, MCV normalizes, and the bone marrow looks normal. However, B12 deficiency also causes irreversible neurological damage (peripheral neuropathy, subacute combined degeneration of the spinal cord, dementia). If you replicate folate without first confirming that B12 is adequate, the anemia resolves and hides the fact that B12 is still deficient, while neurological damage progresses silently. By the time B12 deficiency is finally diagnosed, permanent nerve damage may have occurred. This is why B12 must always be checked before or alongside folate supplementation.
Serum folate rises within days of starting supplementation (oral absorption is rapid). However, tissue folate stores take 1–2 months to fully replete, and hemoglobin/MCV changes lag by 7–10 days (since circulating RBCs live ~120 days and new RBCs must be generated). Homocysteine typically falls within 2–4 weeks of adequate folate repletion. These timescales reflect the underlying biology of RBC lifespan and methylation kinetics, not a protocol for when you should retest — that decision depends on the cause of deficiency and your full biomarker profile.
Methotrexate (immunosuppressant, cancer therapy), trimethoprim (antibiotic), sulfasalazine (IBD treatment), phenytoin and phenobarbital (anticonvulsants), and metformin (diabetes) all impair folate absorption or metabolism. Chronic alcohol use both impairs absorption and reduces hepatic storage. If you take any of these long-term, periodic folate testing is reasonable to catch deficiency before it becomes severe.
Yes. Swedish public health authorities recommend 400 µg/day of folic acid for women planning pregnancy and during the first trimester to prevent neural tube defects. Doses up to 5 mg/day are used therapeutically for deficiency and are also safe in pregnancy. There is no established upper limit of safety for folate in pregnancy in the literature.
RBC folate reflects tissue folate stores over a longer timeframe (months) and may be more sensitive for detecting chronic deficiency. However, RBC folate is not routinely measured in Swedish clinical practice and is more expensive. Serum folate is the standard first-line test in vårdcentral and is adequate for most purposes. RBC folate is useful if serum folate is borderline and you want to confirm chronic depletion, or if you suspect recent supplementation has transiently raised serum folate while tissues remain depleted.
